These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 39268482)

  • 1. Age-specific performance of human papillomavirus E6/E7 mRNA assay versus cytology for primary cervical cancer screening and triage: community-based screening in China.
    Zhang J; Liu G; Yang D; Cui X; Wang C; Wang D; Piao H
    Front Cell Infect Microbiol; 2024; 14():1428071. PubMed ID: 39268482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of human papillomavirus E6/E7 mRNA assay for primary cervical cancer screening and triage: Population-based screening in China.
    Zhang J; Yang D; Cui X; Liu G; Cui Z; Wang C; Piao H
    Front Cell Infect Microbiol; 2022; 12():935071. PubMed ID: 36105144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HPV genotyping and E6/E7 transcript assays for cervical lesion detection in an Asian screening population-Cobas and Aptima HPV tests.
    Wong OGW; Tsun OKL; Tsui EY; Chow JNK; Ip PPC; Cheung ANY
    J Clin Virol; 2018 Dec; 109():13-18. PubMed ID: 30368218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cervical cancer screening cotesting with cytology and MRNA HPV E6/E7 yields high rates of CIN2+ lesions in young women.
    Granados R; Tellez-Safina H; Solis I; Mateos F; Rodriguez-Barbero JM; Aramburu JA; Huertas MA; Bajo P; Camarmo E; Corrales T; Medina P; Calvo B; Martin E; Anta L; Zamora M; Alcaide T
    Diagn Cytopathol; 2017 Dec; 45(12):1065-1072. PubMed ID: 28949442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aptima HPV Assay versus Hybrid Capture
    Cook DA; Smith LW; Law J; Mei W; van Niekerk DJ; Ceballos K; Gondara L; Franco EL; Coldman AJ; Ogilvie GS; Jang D; Chernesky M; Krajden M
    J Clin Virol; 2017 Feb; 87():23-29. PubMed ID: 27988420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of genotyping for human papillomavirus (HPV) 16 18/45 combined with cytology in cervical exfoliated cells in HPV oncogenic mRNA-positive women.
    Wang J; Du Y; Dong J; Zhou Y; Wang P; Zhang X; Chen Y; He P
    Gynecol Oncol; 2019 Apr; 153(1):34-40. PubMed ID: 30630629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [HPV E6 and E7 mRNA combined with HPV 16 and 18 or 45 genotyping testing as a means of cervical cancer opportunistic screening].
    Wang JJ; Dong J; Deng ZX; Wang PF; Zhang XX; Du Y
    Zhonghua Fu Chan Ke Za Zhi; 2019 May; 54(5):301-306. PubMed ID: 31154710
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study.
    Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Halfon P; Ruiz F; Smith JS
    Int J Cancer; 2011 Aug; 129(3):691-701. PubMed ID: 20941740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A study of cervical cancer screening algorithms].
    Zhao FH; Zhang WH; Pan QJ; Zhang X; Chen W; Liu B; Ma JF; Hu SY; Qiao YL
    Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):420-4. PubMed ID: 20819481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus-Based Screening in Mexico.
    Torres-Ibarra L; Cuzick J; Lorincz AT; Spiegelman D; Lazcano-Ponce E; Franco EL; Moscicki AB; Mahmud SM; Wheeler CM; Rivera-Paredez B; Hernández-López R; León-Maldonado L; Salmerón J;
    JAMA Netw Open; 2019 Nov; 2(11):e1915781. PubMed ID: 31747033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of an artificial intelligence-assisted cytological system among screening strategies for a cervical cancer high-risk population.
    Yang W; Jin X; Huang L; Jiang S; Xu J; Fu Y; Song Y; Wang X; Wang X; Yang Z; Meng Y
    BMC Cancer; 2024 Jun; 24(1):776. PubMed ID: 38937664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany.
    Iftner T; Neis KJ; Castanon A; Landy R; Holz B; Woll-Herrmann A; Iftner A; Staebler A; Wallwiener D; Hann von Weyhern C; Neis F; Haedicke-Jarboui J; Martus P; Brucker S; Henes M; Sasieni P
    J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of human papillomavirus (HPV) mRNA testing and HPV 16 and 18/45 genotyping combined with age stratification in the triaging of women with ASC-US cytology.
    Wang J; Dong J; Zhou Y; Wang K; Pan M; Deng Z; Wang P; Du Y; Lu W
    Gynecol Oncol; 2022 Mar; 164(3):607-614. PubMed ID: 34996586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany.
    Iftner T; Becker S; Neis KJ; Castanon A; Iftner A; Holz B; Staebler A; Henes M; Rall K; Haedicke J; von Weyhern CH; Clad A; Brucker S; Sasieni P
    J Clin Microbiol; 2015 Aug; 53(8):2509-16. PubMed ID: 26019212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
    Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
    Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I.
    Wu R; Belinson SE; Du H; Na W; Qu X; Wu R; Liu Y; Wang C; Zhou Y; Zhang L; Belinson JL
    Int J Gynecol Cancer; 2010 Nov; 20(8):1411-4. PubMed ID: 21051986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
    Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
    J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology.
    Castle PE; Reid J; Dockter J; Getman D
    J Clin Virol; 2015 Aug; 69():52-5. PubMed ID: 26209379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Value of Human Papillomavirus E6/E7 mRNA Detection in Screening for Cervical Cancer in Women Positive for Human Papillomavirus DNA or.
    Han L; Husaiyin S; Zhao F; Rezhake R; Niyazi M
    Clin Lab; 2018 Sep; 64(9):1363-1371. PubMed ID: 30274003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.